1[1]Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovasculaRdisease: clinical benefits and possible mechanisms. N Engl J Med, 1995,332:512- 21.
2[2]StamleRJ, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 Primary screenees of the Multiple Risk FactoRIntervention Trial (MRFIT). JAMA, 1986,256:2823 - 8.
3[3]Kwiterovich PO Jr. State - of- the - art update and review: clinical trials of lipid- lowering agents. Am J Cardiol, 1998,82:3- 17U.
4[4]Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovasculaRrisk factor. Am J Cardiol, 1998,81:7 - 12B.
5[5]National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation.and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel Ⅲ) final report. Circulation ,2002,106:3143 - 421.
6[6]Davignon J, Laaksonen E. Low- density lipoprotein- independent effects of statins. CurROpin Lipidol, 1999,10:543 - 59.
7[7]Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med,1999,340:115-26.
8[8]Libby P. MoleculaRbases of the acute coronary syndromes. Circulation 1995,91:2844 - 50.
9[9]Davies MJ, Richardsen PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellulaRlipid, macrophage,and smooth muscle cell content. BRHeart J, 1993,69:377 - 81.
10[10]Alfon J, Pueyo Palazon C, Royo T, et al. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost, 1999,81:822- 7.
